Single-Arm Clinical Study of Zeprumetostat in Combination with Glofitamab + GemOx in Patients with Relapsed/ Refractory DLBCL
Age ≥ 18 years, male or female;
Histologically confirmed diffuse large B-cell lymphoma (DLBCL);
Relapsed/refractory (R/R) disease；
At least one prior line of therapy containing rituximab;
Patient is a candidate for hematopoietic stem cell transplantation.
Prior allogeneic hematopoietic stem cell transplantation.
Primary or secondary central nervous system (CNS) lymphoma or history of CNS lymphoma.
History of severe hypersensitivity or anaphylactic reaction to humanized or murine monoclonal antibodies.